Ernexa Therapeutics Inc. (ERNA) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Ernexa Therapeutics Inc. (ERNA) Earnings Overview
As of June 22, 2026, Ernexa Therapeutics Inc. (ERNA) reported trailing twelve-month net income of -$11M, reflecting -42.7% year-over-year growth. The company earned $-14.38 per diluted share over the past four quarters.
Looking at the long-term picture, ERNA's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2020.
Ernexa Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), CRSP (-$569M net income, -16569.8% margin), BEAM (-$65M net income, -57.2% margin), ERNA has comparable earnings metrics. Compare ERNA vs FATE →
ERNA Earnings vs Peers
Earnings metrics vs comparable public companies
ERNA Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$14M | +68.4% | -$9M | $-56.00 | - | - |
| 2024 | -$45M | -105.6% | -$16M | $-39.25 | -7652.7% | -2693.1% |
| 2023 | -$22M | +11.8% | -$21M | $-102.00 | -31864.7% | -31080.9% |
| 2022 | -$25M | +79.9% | -$33M | $-201.50 | - | - |
| 2021 | -$123M | -1129.3% | -$114M | $-1415.25 | - | - |
| 2020 | $12M | +681.6% | -$7M | $-87.75 | - | - |
| 2019 | -$2M | -690.3% | -$1M | $-712.00 | -10.3% | -6.1% |
| 2018 | $-259,000 | +76.0% | $464,000 | $-96.25 | -1.1% | 2.0% |
| 2017 | -$1M | +63.2% | -$1M | $-441.00 | -5.1% | -6.6% |
| 2016 | -$3M | +59.5% | -$2M | $-1536.00 | -13.1% | -10.2% |
| 2015 | -$7M | - | -$7M | $-3931.50 | -29.5% | -26.9% |
Download Data
Export ERNA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ERNA — Frequently Asked Questions
Quick answers to the most common questions about buying ERNA stock.
What is ERNA earnings per share (EPS)?
ERNA trailing twelve-month (TTM) diluted EPS is $-14.38, reflecting -42.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Ernexa Therapeutics Inc.'s net income?
Ernexa Therapeutics Inc. (ERNA) trailing twelve-month net income is $-11M as of 2025. Earnings declined -42.7% year-over-year.
Is ERNA profitable?
ERNA is not currently profitable on a TTM basis, reporting a net loss of $-11M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ERNA's earnings growth rate?
ERNA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are ERNA's profit margins?
Ernexa Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -686.7%.
Is ERNA growing earnings?
ERNA earnings are declining — EPS fell -42.7% year-over-year. TTM net income dropped to $-11M. This contrasts with the 5-year CAGR of N/A.
What was ERNA's best earnings year?
Ernexa Therapeutics Inc.'s highest annual net income on record is $12M, achieved in fiscal year 2020. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were ERNA's earnings last quarter?
ERNA's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-6.95. For a full breakdown of all quarters, see the quarterly earnings table on this page.